Oxaliplatin
- Generic Name
- Oxaliplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N2O4Pt
- CAS Number
- 61825-94-3
- Unique Ingredient Identifier
- 04ZR38536J
- Background
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...
- Indication
Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
- Associated Conditions
- Advanced Colorectal Cancer, Stage III Colon Cancer
- Associated Therapies
- -
Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05766605
- Locations
- 🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C)
- Conditions
- Interventions
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 120
- Registration Number
- NCT05732493
Serplulimab Combined with CAPEOX + Celecoxib As Neoadjuvant Treatment for Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 50
- Registration Number
- NCT05731726
- Locations
- 🇨🇳
Second Affiliated Hospital School of Medicine Zhejiang University, Hangzhou, Zhejiang, China
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Yu jiren
- Target Recruit Count
- 90
- Registration Number
- NCT05729646
- Locations
- 🇨🇳
The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳Ningbo Second Hospital, Ningbo, Zhejiang, China
🇨🇳Ningbo Medical Center LiHuiLi Hospital, Ningbo, Zhejiang, China
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
- Conditions
- Interventions
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 194
- Registration Number
- NCT05727163
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Liaoning Tumor Hospital & Institute
- Target Recruit Count
- 100
- Registration Number
- NCT05720559
Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 144
- Registration Number
- NCT05701436
- Locations
- 🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT05700448
CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 38
- Registration Number
- NCT05699746
- Locations
- 🇨🇳
Changhai Hospital of Shanghai, Shanghai, Shanghai, China
🇨🇳Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Second Affiliated Hospital Zhejiang University College of Medicine, Hangzhou, Zhejiang, China
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 130
- Registration Number
- NCT05699655
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.